C

Calithera Biosciences Inc
F:2CB

Watchlist Manager
Calithera Biosciences Inc
F:2CB
Watchlist
Price: 3.86 EUR -2.53% Market Closed
Market Cap: 1m EUR
Have any thoughts about
Calithera Biosciences Inc?
Write Note

Relative Value

2CB price has not been updated for more than 5 months. This may indicate that the stock has been delisted.
2CB doesn't have a meaningful market cap.

There is not enough data to reliably calculate the relative value of 2CB.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

2CB Relative Value
Base Case
Not Available
C
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
8.1
vs History
vs Industry
Median 3Y
-0.1
Median 5Y
-0
Industry
23
vs History
vs Industry
Median 3Y
-0
Median 5Y
-0
Industry
23.4
vs History
vs Industry
Median 3Y
-0
Median 5Y
-0
Industry
27.3
vs History
vs Industry
Median 3Y
0.1
Median 5Y
0
Industry
2.6
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
8.1
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
9.6
vs History
vs Industry
Median 3Y
0.6
Median 5Y
0.6
Industry
4.3
vs History
vs Industry
Median 3Y
0.6
Median 5Y
0.6
Industry
3.8
vs History
vs Industry
Median 3Y
0.6
Median 5Y
0.7
Industry
6
vs History
vs Industry
Median 3Y
0.6
Median 5Y
0.7
Industry
3.8
vs History
vs Industry
Median 3Y
-9.8
Median 5Y
-13.1
Industry
4.8

Multiples Across Competitors

2CB Competitors Multiples
Calithera Biosciences Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Calithera Biosciences Inc
F:2CB
1m EUR 0 -0.1 0.6 0.6
FR
Pharnext SCA
OTC:PNEXF
6T USD 37 380 957.8 -177 666.1 -215 743.3 -213 281.4
US
Abbvie Inc
NYSE:ABBV
302.3B USD 5.4 59.5 14.9 22.9
US
Amgen Inc
NASDAQ:AMGN
160.6B USD 4.9 38 17.7 33.4
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
126.3B USD 11.9 -263.2 26.7 28
US
Gilead Sciences Inc
NASDAQ:GILD
117.6B USD 4.2 933 10.4 10.4
US
Epizyme Inc
F:EPE
94.1B EUR 1 884.6 -480.9 -523.7 -509.7
AU
CSL Ltd
ASX:CSL
138.5B AUD 6.1 34.3 21.1 26.3
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
90.4B USD 6.5 19.4 17.9 19.9
US
Seagen Inc
F:SGT
39.3B EUR 18.2 -55.7 -59.8 -54
NL
argenx SE
XBRU:ARGX
33.4B EUR 18.2 -127.9 -102.8 -74.9
P/E Multiple
Earnings Growth
US
C
Calithera Biosciences Inc
F:2CB
Average P/E: 216.8
Negative Multiple: -0.1
N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -177 666.1 N/A
US
Abbvie Inc
NYSE:ABBV
59.5
412%
US
Amgen Inc
NASDAQ:AMGN
38
73%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -263.2
42%
US
Gilead Sciences Inc
NASDAQ:GILD
933
75%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -480.9 N/A
AU
CSL Ltd
ASX:CSL
34.3
65%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
19.4
43%
US
S
Seagen Inc
F:SGT
Negative Multiple: -55.7 N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -127.9 N/A
EV/EBITDA Multiple
EBITDA Growth
US
C
Calithera Biosciences Inc
F:2CB
Average EV/EBITDA: 15.6
0.6
N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -215 743.3 N/A
US
Abbvie Inc
NYSE:ABBV
14.9
28%
US
Amgen Inc
NASDAQ:AMGN
17.7
63%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
26.7
38%
US
Gilead Sciences Inc
NASDAQ:GILD
10.4
12%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -523.7 N/A
AU
CSL Ltd
ASX:CSL
21.1
42%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.9
46%
US
S
Seagen Inc
F:SGT
Negative Multiple: -59.8 N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -102.8 N/A
EV/EBIT Multiple
EBIT Growth
US
C
Calithera Biosciences Inc
F:2CB
Average EV/EBIT: 20.2
0.6
N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -213 281.4 N/A
US
Abbvie Inc
NYSE:ABBV
22.9
88%
US
Amgen Inc
NASDAQ:AMGN
33.4
93%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
28
44%
US
Gilead Sciences Inc
NASDAQ:GILD
10.4
29%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -509.7 N/A
AU
CSL Ltd
ASX:CSL
26.3
55%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
19.9
54%
US
S
Seagen Inc
F:SGT
Negative Multiple: -54 N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -74.9 N/A

See Also

Discover More
Back to Top